ASAS – recent achievements

Slides:



Advertisements
Similar presentations
Ankylosing spondylitis
Advertisements

Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,
Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:
September 5 th – 8 th 2013 Nottingham Conference Centre, United Kingdom
Low back pain Implementing NICE guidance 2009 NICE clinical guideline 88.
What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.
Ankylosing spondylitis
Measuring Signs and Symptoms in Rheumatoid Arthritis David R. Karp, MD, PhD Chief, Rheumatic Diseases UT Southwestern Medical Center David R. Karp, MD,
SPONDYLOARTROPATHIES
Exercise in Ankylosing Spondylitis Prof. Pál Géher MD.
SPONDYLOARTHROPATHIES Prof. Dr. Şansın Tüzün. Definition A family inflammatory arthritides characterized by involvement of both synovium and entheses.
Spondyloarthritis Khusrow Khidri Spondyloarthritis (or spondyloarthropathy) is the name for a family of inflammatory rheumatic diseases that cause.
Ankylosing Spondylitis
GRAPPA Guidelines for PsA: Considerations
Organizational Meeting for the AS-US Working Group Advancing Clinical Research in AS and SpA in the USA Spondylitis Association of America 20 Years of.
Rheumatoid Arthritis Anila Malik GPVTS. Aims To cover the following: What is RA? Diagnostic criteria and clinical features Rheumatoid Factor Investigations.
ANKYLOSING SOPNDYLITIS 僵直性脊椎炎. Definition AS is an inflammatory disorder of unknown etiology that primarily affects the spine, axial skeleton, and large.
Rehabilitation Teaching and Research Unit, Wellington School of Medicine and Health Sciences Outcome measures in psoriatic arthritis Preliminary identification.
ANKYLOSING SONDYLITIS
AM Report 11/24/09 Amy Auerbach  Peak onset between 20 and 30 years  Form of spondyloarthritis (cause inflammation around site of ligament insertion.
Seronegative Spondyloarthropathies
Maxime DOUGADOS Paris-Descartes University, Medicine Faculty; UPRES EA-4058; AP-HP, Cochin Hospital, Rheumatology B Dpt PARIS, France Status versus Changes:
GRAPPA Evidence-Based Treatment Guidelines for Psoriatic Arthritis. Peripheral joint disease Dr. Enrique R. Soriano Dr. Neil J. McHugh.
The Effect of Initial Posture on The Performance of Multi-Joint Reaching Tasks: A Comparison of Joint Excursions Between Individuals With and Without Chronic.
Dr Raj Sengupta Low Back pain. Definitive diagnosis difficult – not made in 85% Distinguish benign, self limiting disease (95%) from serious disease (5%)
NSAIDs and Radiographic Progression in Ankylosing Spondylitis By Abd El-Samad El-Hewala Professor of Rheumatology and Rehabilitation Faculty of Medicine.
OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Philip Helliwell, Arthur Kavanaugh, Gerry Krueger, Peter.
Psoriatic Arthritis Workshop OMERACT May 14 th, 2004 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian.
Welcome to SpA SIG August 2, 2006 MR 304 :
INternational Spondyloarthritis Inter- observer Reliability Exercise – the INSPIRE study. Gladman DD, Inman RD, Cook R, Maksymowych W, van der Heijde D,
Assessment of enthesitis in psoriatic arthritis
OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Oliver FitzGerald, Philip Helliwell, Arthur Kavanaugh,
Rheumatology teaching session GP ST2 year 8/9/10.
Axial Spondyloarthritis (SpA): Representative Values of Sensitivity and Specificity for Several Tests with the Resulting LRs *LR+ = sensitivity/(1 – specificity);
1 Assessing Disease Activity Janice Booth Rheumatology Nurse Practitioner January 2012.
Spondyloarthropathies. Introduction Spondyloarthropathy (Spondloarthritis) – Term for a group of chronic diseases – Affecting the joints of the spine.
GRAPPA Meeting, Oct. 16, 2004 San Antonio, Texas Patient Global Question Alberto Cauli Rheumatology Division University of Cagliari, Italy Director Prof.
Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.
OMERACT Workshop Outcome Measures in Psoriatic Arthritis
Infectious arthritis Bacterial Viral Other Postinfectious (reactive) arthritis Rheumatic fever Reactive arthritis Enteric infection Other seronegative.
Outcome Measures in PsA Philip Mease MD Seattle, WA.
Psoriatic Arthritis Workshop Part 2 OMERACT May 15 th, 2004 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heidje, Christian.
GRAPPA Guidelines for PsA: Considerations GRAPPA Guidelines Mission Statement: “To develop guidelines, based upon the best scientific evidence, for the.
Perspectives on Clinical Outcomes of Studies of Products for Use in Cartilage Repair Marc C. Hochberg, MD, MPH Professor of Medicine Head, Division of.
OMERACT 8 PsA Module Proposal Submitted by: Dafna Gladman and Philip Mease.
GRAPPA Committee Reports and Outcome measures Dafna D. Gladman, MD, FRCPC Professor of Medicine, University of Toronto Director, PsA Program, University.
Psoriatic Arthritis Workshop OMERACT 7 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian Antoni, Philip.
Managing your Inflammatory Back Pain Dr Amanda Isdale Rheumatologist York Teaching Hospital.
What’s Hot in Spondyloarthritis
Department Of Rheumatology : Prevalence of LBA in a tertiary care Naval hospital Surg Cdr A Singhal, Brig R Ramasethu, Surg Cmde KI Mathai, Dr P Malviya.
Backgrond  Ankylosing spondylitis Condition in the spondyloarthritis (SpA) family of disease Chronic inflammatory arthritis characterized by sacroiliitis,
3e Initiative 2009 How to investigate and follow-up Undifferentiated Peripheral Inflammatory Arthritis? Case 2.
Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71: doi: /annrheumdis
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis R1 신가영 / Modulator Prof. 이연아 N Engl J Med 2015; 373: Philip J.
Identifying Early Inflammatory Arthritis
Exploring the Natural History of Bone Marrow Oedema Lesions in
AS – the facts! Andrew Keat.
강직성 척추염의 치료 경희대학교 의과대학 류마티스 내과 이상훈.
Chief investigator- Dr. Kripasindhu Gantait, Associate Professor
Approach to Diagnosis of Ankylosing Spondylitis Iraj Salehi-Abari MD
Ankylosing Spondylitis
Enteropathic Arthropathy
FINAL Recommendations
WORCESTERSHIRE PATHWAY for use of CYTOKINE MODULATORS in
Slide set should, if possible, not exceed 20 Slides
What on earth is Spondyloarthritis
Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.
Axial Spondyloarthropathy
Dr Sarah Levy Consultant Rheumatologist CUH
Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.
Presentation transcript:

ASAS – recent achievements General remarks Improvement Criteria Anti-TNF Treatment recommendations Prof.J.Braun Rheumazentrum Ruhrgebiet Herne Free University Berlin Germany

SpA subtypes AS Ankylosing spondylitis (AS) Undifferentiated SpA EULAR proposal for terminology: Spondyloarthritis (SpA) Francois R, Eulderink F, Bywaters EGL. Ann Rheum Dis 1995; 54:615-625 SpA subtypes Ankylosing spondylitis (AS) Undifferentiated SpA Psoriatic SpA Reactive SpA SpA associated with chronic inflammatory bowel diseases Outcome ! AS

Modified New York Criteria 1984 for Diagnosis/Classification of Ankylosing Spondylitis van der Linden et al. A & R 1984 Clinical Criteria inflammatory back pain (Calin 1977) reduced spinal mobility in 2 planes ( < 3 cm) reduced thoracic excursion (< 3cm) Radiologic Criterium sacroiliitis of > grade II bilat, > grade II unilat

ESSG Criteria 1991 for Spondyloarthritis Dougados M et al. A&R 1991 2 major criteria inflammatory back pain asymmetric oligoarthritis of the lower limbs 7 minor criteria enthesitis (heel) alternating buttock pain sacroiliitis (radiographic) family history of SpA psoriasis inflammatory bowel disease symptomatic preceding infection (urogenital, enteral)

Undifferentiated Spondyloarthritis unequivocal SpA symptoms, but no definitive Spondylitis ankylosans Psoriatic arthritis Reactive arthritis Arthritis associated with CED covers early cases abortive forms overlaps, transitions differentiation towards AS sacroiliitis < grade II ReA clinical picture, antibodies, PCR 30-50% development of AS

Assessments in Spondyloarthritides Diagnosis 5 subgroups (AS, PSpA, uSpA, RSpA, SpAIBD) Outcome, Monitoring Disease activity (BASDAI) Pain (VAS, NRS scales) Patient global assessment (VAS, NRS scales) Inflammation (morning stiffness, CRP, ESR) Localisation (axial, peripheral, organ manifestations) Spinal mobility (BASMI) Function (BASFI) Damage (mod. SASSS, BASRI, MRI score) Quality of life (SF-36, AS-Quol)

Ankylosing spondylitis - detection of spinal inflammation by MRI Braun J et al. Rheum Dis Clin North Am 1998; 24: 697-735 Brandt J et al. Arthritis Rheum 2000; 43: 1346-52

Scoring active spinal inflammation in ankylosing spondylitis by ASspiMRI-a Braun J, van der Heijde D. Best Pract Res Clin Rheumatol 2002 Sep;16(4): 573-604

Relative changes of MRI scores on infliximab (n=9) or placebo (n=11) therapy Post-Gad. STIR T1 %-change Braun J et al., Arthritis Rheum 2003 April; 48: 1126

Assessments in Spondyloarthritides Inflammatory back pain (questionnaires, pain scales) Spinal mobility BASMI, chest expansion, lat. Schober Joint counts (44 J.C.) Enthesitis scores (MASES, ..) Dactylitis Organ involvement anterior uveitis (n flares) psoriasis colitis other organ involvement

ASAS working group criteria for improvement and remission in AS (JJ Anderson, D van der Heijde, DT Felson, M Dougados. A&R 2001;) 20% Improvement: improvement of at least 20% and absolute improvement of at least 10 on a 0-100 scale in at least 3 of the following domains: Patient global Pain Function (BASFI) Inflammation (last 2 questions of the BASDAI on morning stiffness) and absence of deterioration of at least 20% and absolute change of at least 10 on a 0-100 scale in the potential remaining domain Partial remission: a value below 20 on a 0-100 scale in each of the 4 domains

Improvement criteria for treatment with biologics in AS – a data driven analysis based on the RCT with Infliximab (n=69) Domains: 1. Metrology (BASMI) 4. Patients global (VAS) 2. CRP 5. Function (BASFI) 3. Pain on VAS 6. Morning stiffness/BASDAI Improvement definition % improving in the placebo-treated group % improving in the infliximab-treated group 2  20% change in any 5 of 6 2.9 67.7 31.9  20% change in any 4 of 5 (without CRP) 8.6 76.5 32.6  30% change in any 4 of 6 5.7 64.7 26.5 (incl. BASDAI instead of Morning stiffness) 5,7 67,6 28,6 Reference criteria  50% change of the BASDAI 58.8 19.6  40% change of the BASDAI 23.5  50% ASAS 52.9 18.7  40% ASAS

Development of a consensus on anti-TNF Therapy in ankylosing spondylitis 1st Meeting in Berlin in January 2002 First Questionnaire Results ASAS Delphi Exercise (M.Dougados) ASAS Meeting Stockholm: decision Preparation of 2nd Berlin Meeting ASAS Delphi exercise 2nd Meeting in Berlin in January 2003 Publication of two papers in Ann Rheum Dis 9/2003 ASAS consensus Results of Delphi exercise

ASAS members participation First questionnaire Full ASAS members participation : 61% (36/59) Second questionnaire Full ASAS members participation : 56% (33/59)

Question 1 ASAS members estimation Percentage of patients potentially candidate for biologics

Question 3 Do you consider that the sensitivity and specificity of the future practice guidelines for biologics in AS should be assessed ? (gold standard = rheumatologists’ opinion) Yes : 89% If yes, do you consider that sensitivity and specificity should be assessed before publishing the ASAS recommendations? Yes : 52% No : 48%

EBM and/or Experts’ opinion: 88% Question 1 Should we go for strict guidelines (high thresholds) or for flexible guidelines (low thresholds)? Strict : 40% Flexible : 60% Must the guidelines and proposed cut-offs always evidence based, or experts agreed, where evidence is lacking? Strict EBM : 12% EBM and/or Experts’ opinion: 88% Question 2

When can biologics initiation can be considered, in daily practice? Topic 1 When can biologics initiation can be considered, in daily practice?

Question 4 Do you agree with the separation into 3 categories : isolated axial involvement, peripheral arthritis, enthesitis? Yes : 71% Disagreement was mainly because : artificial separation frequent association of the 3 categories, especially enthesitis with the 2 others  “enthesitis should not be considered as a distinct entity” does not take into account the “weight” of the different categories (one swollen joint or one painful enthesis doesn't seem strong enough as convincing indication)

Question 5 (1/3) Are the criteria selected by the Delphi exercise for axial involvement acceptable for you? Yes : 75%

Number of ASAS members who selected the item Question 5 (2/3) Disagreement was because : 5a. Chosen variables Refractory to NSAIDs 0 Patient’s global assessment 0 Inflammatory pain 0 Functional impairment 1 Laboratory parameters (ESR, CRP) 3 Number of ASAS members who selected the item 5b. Chosen cut off  2 NSAIDs (Refractory to NSAIDs) 2 VAS  40 mm (Patient’s global assessment) 3 VAS  40 mm (Inflammatory pain) 3 BASFI  40 (Functional impairment ) 2 ESR > 28 (Laboratory parameters) 3 abnormal range CRP (Laboratory parameters) 3

Number of ASAS members who selected the item Question 5 (3/3) Disagreement was because : Number of ASAS members who selected the item 5c. 3 of 4 rule Biologics initiation can be based on patient derived variables only 5 Biologics initiation can be considered for patient without pain 3 Function is not relevant to consider biologics initiation 2 Pain is not relevant enough to consider biologics initiation 0 Patient’s global is not relevant enough 1 BASDAI is more relevant 3 Other propositions Objective parameters needed 3 Lacking past history and severity of the disease 1 Should treat patients equally irrespective of ESR or CRP 1 3 months duration NSAIDs period too long 1

Question 7 (1/3) Are the criteria selected by the Delphi exercise for enthesitis presentation acceptable for you? Yes : 69%

Question 8 How do you rate the view considering 3 groups of variables (patient derived variables, physician derived variables, technical) compared to the results of the Delphi exercise? Much better 11% Somewhat better 30% Similar 33% Somewhat worse 22% Much worse 0% I don’t know 3% 41% 22%

Question 4 Concerning the initiation of biologics in AS, which of the following do you feel should be considered?

Question 10 (1/3) Concerning the objective assessments, what is your opinion concerning the definition of an active disease?

Variables to collect in order to evaluate biologics efficacy Question 12 (1/2) Variables to collect in order to evaluate biologics efficacy Acute phase reactants Function Spinal mobility

International ASAS consensus statement for the clinical use of anti-TNFa-treatment in patients with Ankylosing Spondylitis in daily practice Jürgen Braun, Thao Pham, Jochen Sieper, John Davis, Sjef van der Linden, Maxime Dougados and Désirée van der Heijde for the ASAS Working Group Berlin, Herne, Marseille, San Francisco, Paris, Maastricht

List of ASAS members/ participants/questionnaire co-workers 1.   Adebajo A O, UK 2.   Amor B, France 3.   Boers M, NL 4.   Boonen A, NL 5.   Bosch van den, F, Belgium 6.   Brandt J, Germany 7.   Braun J, Germany * 8.   Burgos Vargas R, Mexico 9.   Calin A, UK 10. Clegg D, USA 11. Collantes Estevez E, Spain 12. Darmawan J, Indonesia 13. Davis J, USA * 14. Dougados M, France * 15. Dijkmans B A C, NL 16. Edmonds J, Australia 17. Emery P, UK 18. Feltelius N, Sweden 19. Géher P, Hungary 20. Guillemin F, France 21. Heijde van der D, NL* 22. Horst v.d.-Bruinsma I, NL 23. Khan MA, USA 24. Kirazli J, Turkey 25. Kuipers J, Germany 26. Landewé R, NL 27. Leirisalo-Repo M, Finland 28. Linden v. d. S, NL * 29. Linssen A., NL 30. Listing J, Germany 31. Maetzel A, Canada 32. Maksymowych W, Canada 33. Mielants H, Belgium 34. Olivieri I., Italy 35. Peloso P, USA 36. Pham T, France 37. Reveille J, USA 38. Riel van, NL 39. Rudwaleit M, Germany 40. Russell A S, Canada 41. Salvarani, C., Italy 42. Sieper J., Germany * 43. Stone M A, Canada 44. Sturrock R, UK 45. Yu, D, USA 46. Zeidler H, Germany   * Steering Committee Members of ASAS

Why are guidelines for the use of anti-TNFa treatment in AS needed? Introduction of anti-TNF agents has led to new therapeutic opportunities in the spondyloarthritides Efficacy of infliximab and etanercept in AS Approval of infliximab and etanercept for AS Uncertainty regarding the optimal use and potential side effects on anti-TNF agents Considerable costs of anti -TNF therapy

Methodology employed to develop the guidelines Review of the current literature Expert opinion Delphi exercise Consensus meeting of the international assessment in AS (ASAS) working group

Questions concerning the use of anti-TNFa therapy in AS What patients are appropriate candidates to consider for anti-TNF therapy ? How should response to anti-TNF therapy be measured ? When should anti-TNF therapy be continued and discontinued ?

What patients are candidates to consider for anti-TNFa therapy? Persistence of active disease Threat of severe disease (damage) Likelihood of response to therapy

International consensus on anti-TNFa therapy in ankylosing spondylitis Diagnosis Disease activity Failure of conventional Treatment Absence of contraindications Monitoring Discontinuation Initiation Monitoring Discontinuation ASAS Meeting in Berlin January 2003 Braun J et al. Ann Rheum Dis 9/2003

1. Diagnosis of ankylosing spondylitis Patients ‘normally’ fulfilling the modified New York Criteria for definitive AS (1984 van der Linden et al.) Radiological criterion Sacroiliitis, grade  II bilaterally or grade III to IV unilaterally  

1. Diagnosis of ankylosing spondylitis Clinical criteria (1 out of the following 3) Low back pain and stiffness for more than 3 months that improves with exercise but is not relieved by rest Limitation of motion of the lumbar spine in both the sagittal and frontal planes Limitation of chest expansion relative to normal values correlated for age and sex

2. Disease activity before anti-TNFa therapy I. active disease for at least 4 weeks II. BASDAI  4 (0-10) and an expert* opinion**   * The expert is a physician, usually a rheumatologist, with expertise in inflammatory back pain and the use of biologics. The expert should be locally defined. ** An expert opinion is comprised of both clinical features (history and examination) and either serum acute phase reactant levels or imaging results, such as radiographs demonstrating rapid progression or MRI scans indicating inflammation.

3. Treatment failure before anti-TNFa therapy Different for patients with predominantly Axial disease Peripheral disease Entheseal disease

3. Treatment failure before anti-TNFa therapy All patients must have had adequate therapeutic trials of at least 2 NSAIDs. An adequate therapeutic trial is defined as : Treatment for at least 3 months at maximal recommended or tolerated anti-inflammatory dose unless contraindicated Treatment for < 3 months where treatment was withdrawn because of intolerance, toxicity, or contraindications.

3. Treatment failure before anti-TNFa therapy Patients with symptomatic peripheral arthritis (normally having or failing local steroid injection for those with oligoarticular involvement) must have had adequate therapeutic trial of both NSAIDs and salazopyrine*   Salazopyrine: Treatment for at least 4 months at standard target dose or maximally tolerated dose unless contraindicated or not tolerated. Treatment for less than 4 months, where treatment was withdrawn because of intolerance or toxicity or contraindicated.

3. Treatment failure before anti-TNFa therapy Patients with symptomatic enthesitis must have had an adequate therapeutic trial of at least two local steroid injections unless contraindicated.  

4. Contraindications for anti-TNFa therapy active infection patients at high risk of infection including: chronic leg ulcer previous tuberculosis (note: please follow local recommendations for prevention or treatment) septic arthritis of a native joint within the last 12 months sepsis of a prosthetic joint within the last 12 months, or indefinitely if the joint remains in situ persistent or recurrent chest infections Indwelling urinary catheter

4. Contraindications for anti-TNFa therapy women who are pregnant or breastfeeding; effective contraception must be practiced history of Lupus or Multiple Sclerosis malignancy or pre-malignancy states excluding basal cell carcinoma malignancies diagnosed and treated more than 10 years previously (where the probability of total cure is very high)

5. Monitoring of anti-TNFa therapy BASDAI ASAS core set

BASDAI (0 – 10) [past week, VAS, NRS] fatigue/tiredness neck, back, or hip pain pain/swelling in joints other than neck, back or hips discomfort from any areas tender to touch or pressure duration and intensity of morning stiffness from time of awakening (up to 120 minutes)

ASAS core set of assessments for daily practice Physical function (BASFI or Dougados functional index) Pain (VAS, last week, spine at night, due to AS and VAS, last week, spine due to AS) Spinal mobility (chest expansion and modified Schober and occiput to wall distance and lateral lumbar flexion) Patient’s global assessment (VAS, last week) Stiffness (duration of morning stiffness, spine, last week) Peripheral joints and entheses (number of swollen joints [44 joints count], enthesitis score such as developed in Maastricht, Berlin or San Francisco) Acute phase reactants (ESR or CRP) Fatigue (VAS) van der Heijde et al. J Rheumatol 1997

6. Discontinuation of anti-TNFa therapy < 50% relative change or absolute change of 20 mm of BASDAI and Expert Opinion : Continuation yes/no after 6 to 12 weeks of treatment

Further development Implementation in clinical practice Regular update (2005) Recommendations will be published in the Annals of Rheumatic Diseases and become available on the website of the ARD and ASAS (publication of U.S.- specific Comments)

Personal proposal: link PsA working group to ASAS Future: Assessments in SpA working group ?